Navigation Links
The interruption of biological rhythms during chemotherapy worsen its side effects
Date:5/21/2014

Patients receiving chemical treatment for cancer often suffer fatigue and body weight loss, two of the most worrying effects of this therapy linked to the alteration of their circadian rhythms.

The circadian system, better known as our biological clock, is responsible for coordinating all the processes that take place in our organism.

If it does not function correctly, what is known as a circadian disruption or chronodisruption, has for years been linked to an increased incidence of cancer, obesity, diabetes, depression, cognitive problems or cardiovascular diseases.

"Also, circadian disruption in cancer patients aggravates the prognosis of the disease and the chance of survival for these patients diminishes," Elisabet Ortiz Tudela, a researcher at the University of Murcia, told SINC.

The expert is the author of a study published in the 'International Journal of Cancer', which reveals the importance of assessing how the circadian system works in order to prevent chronodisruption and to implement measures to strengthen the biological clock in people whose system is damaged.

However, measuring how the biological clock works is not easy in humans given that the "machinery" is located within the suprachiasmatic nucleus in the hypothalamus, deep within the brain.

"Therefore, it is impossible to directly assess how the clock Works," adds Ortiz. "Today, biological rhythms are studied which are clock "interruptions" and which enable us to indirectly assess the status of the circadian system".

One of the most studied "interruptions", which can be measured with non-invasive techniques and during long periods of time, is the activity-rest rhythm.

Chronotherapy for cancer

Researchers characterised the evolution of the circadian system in cancer patients submitted to a standard chronotherapy protocol (synchronisation of medication with natural rhythms). The activity-rest rhythm was recorded in 49 patients with advanced cancer while being given a standard chronomodulated chemotherapy cycle, which resulted in circadian disruption.

All the parameters calculated according to the activity-rest rhythm worsened considerably with the chemotherapy. Also, the existence of circadian disruption during the treatment was linked to greater fatigue and body weight loss, two of the most worrying associated factors for doctors.

"After the treatment and at the end of the study, the mean values of all the parameters were recovered to near baseline values," stated the scientist from the institution in Murcia.

The results show four different patterns with regard to the evolution of the circadian system in response to the treatment: in 9.5% of the patients the activity-rest rhythm remained stable despite the chemotherapy, 14.3% of patients showed some improvement, 31% suffered alterations in response to the treatment and recovered completely at the end of the study and in 45% of these deterioration sustained, possibly through inadequate dosing or incorrect timing.

This effect shows the great differences between individuals, which could affect the effectiveness of the treatment.

"Minimising circadian disruption through the personalisation of chronotherapy delivery could help to improve clinical tolerability and potentially contribute towards the treatment being more effective," concludes Ortiz.


'/>"/>

Contact: Press Office
info@agenciasinc.es
34-914-251-820
FECYT - Spanish Foundation for Science and Technology
Source:Eurekalert

Related medicine news :

1. Results of the ARCTIC-INTERRUPTION trial presented at TCT 2013
2. A shorter interruption of anti-thrombotics does not influence peri-operative complications
3. Differences in generic pill characteristics may lead to interruptions in essential medication use
4. Genetic alterations in shared biological pathways as major risk factor for ASD
5. Potential biological factor contributing to racial disparities in prostate cancer
6. GeoScience.net Publishes 40,188 New Abstracts on Biological Alteration
7. Alcohol-related aggression: Social and neurobiological factors
8. Houston we have a problem: Microgravity accelerates biological aging
9. UCLA scientist uncovers biological clock able to measure age of most human tissues
10. Greek crisis has biological health effects
11. NIH Grant to support Mount Sinai Research Program to Create Biological Network Model of Alzheimer’s Disease in partnership with New York Stem Cell Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: